2022年1月12日 · The monoclonal antibody therapies authorized for emergency use by the Food and Drug Administration (FDA) to treat COVID-19 are: Bamlanivimab plus etesevimab. Casirivimab plus imdevimab (known as REGEN-COV). Sotrovimab. However, only sotrovimab may be effective against the newest variants of COVID-19, including omicron.

Today, the FDA issued an emergency use authorization for two monoclonal antibodies administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients who are...

1 天前 · PEMGARDA™ (pemivibart) is a half-life extended investigational monoclonal antibody (mAb). PEMGARDA was engineered from adintrevimab, Invivyd's investigational mAb that has a robust safety data package and provided evidence of clinical efficacy in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19.

2021年4月1日 · In this Special Feature, we look at monoclonal antibody therapy for COVID-19. We cover what it is, the evidence for it, and the research currently underway.

2025年1月26日 · Antibody therapies are a type of biologic. They are typically monoclonal antibodies selected to bind to a particular protein (often a cell-surface protein), and produced using recombinant DNA...

Monoclonal antibodies are no longer available to treat Covid in the U.S. after the FDA rescinded its authorization of the last one standing, bebtelovimab.

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate...

In this revision of the EUA, bamlanivimab and etesevimab, administered together, are authorized for use after exposure to the virus and are not authorized for pre-exposure prophylaxis to prevent...

With the declaration of the end of the COVID-19 pandemic in 2023, WHO launched a new initiative called Preparedness and Resilience for Emerging Threats, which aims to harness the lessons learnt from past pandemics. 1 The protection of immunocompromised populations from COVID-19 was, and remains, a major challenge to health policy makers globally. 2–5 In the UK, the COVID-19 Autumn 2024 ...

2023年8月24日 · Introduction. In July 2023, the Food and Drug Administration (FDA) approved nirsevimab (Beyfortus, Sanofi and AstraZeneca), a long-acting monoclonal antibody, for the prevention of respiratory syncytial virus (RSV)–associated lower respiratory tract infection (LRTI) among infants and children aged <24 months (1).*Nirsevimab is administered as a 1-dose intramuscular injection shortly before ...